drugset / Trial / NCT03868436

PENTHROX™ in the Canadian Emergency Department (ED)

NCT03868436

Phase 4 Completed 99 enrolled Purdue Pharma, Canada
NaSingle-groupOpen-labelTreatment

Summary

This Canadian, multi-centre, prospective, real world study is designed to evaluate the effectiveness of low dose methoxyflurane (MEOF) (PENTHROX™) for the treatment of moderate to severe pain associated with trauma in the Canadian ED.

Timeline

Start
2019-04-08
Primary completion
2020-03-30
Completion
2020-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methoxyflurane Small molecule 3 ml Inhaled

Indications

No indication recorded.